AI in Claims Review: Consumer Protections and Regulatory Trends

The integration of artificial intelligence into the health insurance claims review cycle is fundamentally altering how patients access medical care. As insurers increasingly rely on AI to manage prior authorization—the process requiring provider approval before a specific treatment or medication is covered—the focus of health policy has shifted toward establishing consumer protections to prevent algorithmic errors from denying necessary care.

Prior authorization is intended to ensure that medical services are necessary, and appropriate. However, the use of AI to automate these reviews introduces risks of systemic denials if the algorithms are designed to prioritize cost-savings over individual patient clinical needs. According to a May 6, 2026, analysis by KFF, the current regulatory landscape is a patchwork of federal guidance and emerging state laws aimed at ensuring these tools do not create barriers to essential health services.

Consumer Protections in AI-Driven Reviews

The primary concern regarding AI in claims review is the black box nature of many algorithms, where the reasoning behind a denial is not transparent to the physician or the patient. Consumer protections currently center on the requirement for human oversight, often referred to as human-in-the-loop (HITL) protocols.

These protections are designed to ensure that an AI does not have the final authority to deny a claim. Instead, a qualified medical professional must review the AI’s suggestion and make the ultimate determination. Key areas of focus for consumer protection include:

• Transparency requirements that notify patients and providers when AI is used in the decision-making process.
• The right to a timely appeal conducted by a human clinician who was not involved in the initial AI-assisted review.
• Standardized data inputs to prevent AI from using biased or incomplete medical records to justify a denial.
• Requirements for insurers to prove that AI tools are updated with the latest clinical guidelines.

Without these safeguards, there is a risk that AI could apply broad clinical guidelines too rigidly, ignoring the specific comorbidities or unique circumstances of an individual patient.

Federal Regulatory Approach

The Trump administration has generally maintained an approach to AI regulation that prioritizes innovation and market-led growth over restrictive federal mandates. This philosophy typically favors the use of non-binding frameworks and industry guidelines rather than rigid, prescriptive rules that could stifle the development of new Health I.T. Tools.

In the context of health insurance, this approach suggests a preference for agency-level guidance—such as from the Centers for Medicare & Medicaid Services (CMS)—rather than sweeping new federal laws. The goal is to allow AI to reduce administrative burdens and speed up the authorization process, provided that existing patient protections under the Affordable Care Act and other statutes are maintained.

Legislative Trends and Congressional Action

While the executive branch focuses on a flexible regulatory environment, Congress is considering more structured AI legislation. Lawmakers are examining how to codify transparency and accountability into law to protect patients from algorithmic bias and errors.

Current legislative discussions are centered on creating a federal standard for AI transparency in healthcare. This would potentially require insurers to disclose the specific logic or parameters the AI uses to determine if a treatment is medically necessary. By standardizing these disclosures, Congress aims to give providers a clearer path to challenge incorrect denials.

some proposed legislation seeks to limit the extent to which AI can be used to automate the entire claims cycle, ensuring that the human element of medical judgment remains central to the process.

State-Level Intervention

In the absence of a comprehensive federal AI law, several states have taken the lead in implementing consumer protections. Some state insurance commissioners have introduced rules that explicitly forbid the use of AI as the sole basis for a claim denial.

These state-level actions often include stricter timelines for appeals and mandates that the human reviewer must provide a detailed clinical explanation for the denial, rather than simply citing an algorithmic output. This divergence between state and federal approaches creates a complex environment for national insurers, who must navigate varying requirements across different jurisdictions.

The tension between the efficiency gains offered by AI and the necessity of patient safety continues to drive the evolution of health insurance policy. As these tools become more sophisticated, the focus remains on ensuring that technology supports, rather than replaces, the clinical relationship between patients and their providers.